Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.44 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839924 | 0.87 | HTR6 (0.64) | HTR6LMNAALDH1A1THRBTSHR | |
| SCHEMBL3840327 | 0.87 | HTR6 (0.59) | HTR6LMNAALDH1A1THRBTSHR | |
| SCHEMBL3840775 | 0.83 | HTR6 (0.48) | HTR6 | |
| SCHEMBL3840250 | 0.80 | HTR6 (0.67) | HTR6LMNAALDH1A1THRBTSHR | |
| SCHEMBL10263415 | 0.78 | HTR6 (0.66) | HTR6 | |
| SCHEMBL21869968 | 0.78 | HTR6 (0.66) | HTR6 | |
| SCHEMBL3840397 | 0.78 | HTR6 (0.61) | HTR6 | |
| SCHEMBL3841615 | 0.77 | HTR2C (0.53) | HTR6 | |
| SCHEMBL5509514 | 0.77 | HTR6 (0.67) | HTR6 | |
| SCHEMBL6001969 | 0.76 | CHRNA7 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | claimed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | claimed |
| JP-2008524274-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1831189-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | claimed |
| WO-2006066745-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1831189-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | disclosed |
| WO-2006066745-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | HTR6 1638/4885LMNA 2341/4885HTT 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.